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Streptomyces venezuelae is a promising chassis in synthetic biology for fine chemical and 
secondary metabolite pathway engineering. The potential of S. venezuelae could be further 
realized by expanding its capability with the introduction of its own in vitro transcription-
translation (TX-TL) system. TX-TL is a fast and expanding technology for bottom-up 
design of complex gene expression tools, biosensors and protein manufacturing. Herein, 
we introduce a S. venezuelae TX-TL platform by reporting a streamlined protocol for cell-
extract preparation, demonstrating high-yield synthesis of a codon-optimized sfGFP 
reporter and the prototyping of a synthetic tetracycline-inducible promoter in S. 
venezuelae TX-TL based on the TetO-TetR repressor system. The aim of this system is to 
provide a host for the homologous production of exotic enzymes from Actinobacteria 
secondary metabolism in vitro.  As an example, we demonstrate the soluble synthesis of a 






Streptomyces belongs to the high G+C (%) Actinomycetes soil bacteria and represents the 
leading source of natural antibiotics such as streptomycin and tetracycline [1]. Recently, 
Streptomyces venezuelae, the chloramphenicol producer, has been adopted by synthetic 
biology for its use in metabolic engineering [2], since it is relatively well characterized, has 
strong promoter tools and genome engineering plasmids for integration [3Ȃ5]. Whilst it is 
not as characterized as Streptomyces coelicolor A3(2), in contrast, S. venezuelae provides 
significant advantages such as a fast growth (~ TD = 40 min) and no aggregation during 
liquid culture [3]. One potential route for the further development of S. venezuelae and the 
characterization of its genetic parts is the introduction of an in vitro transcription-
translation system (TX-TL). TX-TL has recently been developed as a highly adaptable tool 
for bottom-up synthetic biology and is based on a whole-cell extract [6Ȃ9] to synthesize 
recombinant proteins from the chemical building blocks of life. 
 
One potential new application for TX-TL is the direct assembly of natural products from 
biosynthetic genes, as recently pioneered in E. coli TX-TL for the co-synthesis of two large 
(> 100 kDa) non-ribosomal peptide synthetases [10]. Indeed, for expression of genes from 
Streptomyces species, E. coli may not be the ideal host chassis in all cases - e.g. poor codon 
usage, solubility issues, post-translational modification [11] or an absence of exotic 
precursors, such as coenzyme F420 [12]. Moreover, utilizing a host homologous to the 
chosen pathway has previously proved successful for acquiring soluble and active 
pathway enzymes [13], whereas E. coli accumulated only inclusion bodies. Another caveat 
to the use of E. coli is the potential inhibition of TX-TL machinery if the target products 
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possess antimicrobial activities, whereas many Streptomyces species are known to provide 
their own resistance strategies to a variety of antimicrobials [14]. 
 
There is past evidence to suggest that a range of Streptomyces species are suitable for TX-
TL [15,16], however, it is unclear from recent literature what is the true productivity of a 
Streptomyces TX-TL system. TX-TL can provide a tool to rapidly prototype the cellular 
machinery of synthetic biology hosts [17]. Herein, we provide evidence for the 
development of a high-activity S. venezuelae TX-TL system utilizing the kasOp* promoter 
as a standard for cell-extract optimization [18]. In summary, we demonstrate high-yield 
synthesis of up to 1.3 PM superfolder GFP (sfGFP), prototype a TetR-TetO gene expression 
tool [19] and synthesise a selection of enzymes from the S. rimosus (ATCC 10970) 





2 Materials and methods 




3 Results  
 
3.1 Optimising a high-activity S. venezuelae cell-extract 
A general protocol for Streptomyces TX-TL was previously developed by Hopwood, Bibb 
and colleagues [21]. Significantly, a number of costly and therefore undesirable 
components are present in this original protocol, such as Staphylococcal nuclease and 
pyruvate kinase. To try a different low-cost strategy, we prepared a S. venezuelae cell-
extract using the original Streptomyces method and tested its activity with a 3-
phosphoglyceric acid (3-PGA) energy buffer derived from E. coli TX-TL [22]. Cell-extracts 
were tested for activity using sfGFP reporter coupled to a high-activity kasOp* promoter. 
 
The process of cell-extract preparation can be divided into five stages in the order of (1) 
cell-growth, (2) washing, (3) sonication, (4) run-off and (5) dialysis. We merged the 
Streptomyces method for stages (1-2) with the E. coli TX-TL methodology for stages (3-5). 
This new protocol provided a significant baseline level of sfGFP fluorescence (154 nM), 
whereas by following the separate protocols on their own, only trace levels of sfGFP 
fluorescence (~5 nM) were observed (data not shown). Next, by focusing on the 
preparation of the cell-extract and the reaction conditions, key variables (Fig. 1A-F) were 
optimised such as cell-lysis by sonication, run-off, dialysis and the concentration of TX-TL 
reaction components including polyethylene glycol (PEG), Mg-glutamate and K-glutamate. 
Each of these single components was varied and assessed during two rounds of parameter 
optimization to establish a streamlined protocol for S. venezuelae TX-TL, providing a 
maximum yield of 1.31 PM sfGFP (36 Pg mL-1), which demonstrated an 8.5-fold increase 
over the original base levels. In brief, a significant gain in activity was observed by varying 
the levels of the molecular crowding agent PEG and Mg-/K-glutamate salt (Fig. 1B, C), 
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whilst the sonication duration did not appear to alter the activity. Dialysis in S30-SC buffer 
was also found to reduce cell-extract activity by 18 %. 
 
3.2 TX-TL protein synthesis requires 20-40 nM of DNA for translation saturation 
The S. venezuelae cell-extracts were active for up to 4 hours of TX-TL batch synthesis. 
Interestingly, the signal intensity of sfGFP in both real-time TX-TL fluorescence and 
Western blot end-point samples demonstrated a proportional increase in sfGFP 
production with plasmid DNA concentration, which saturate between 20-40 nM of DNA in 
three independent batches (Fig. 2A, 2B). For comparison, in E. coli Rosetta TX-TL extracts, 
saturation requires 10-15 nM [17]. In addition, for S. venezuelae TX-TL, the fluorescence 
signal for sfGFP was observed to decay after approximately 4 hours of incubation. This 
also occurred with incubations pre-spiked with purified sfGFP (Supporting information, 
Fig. S2). The signal decay was suspected to be due to host proteases, however, a Western 
blot prepared with anti-GFP primary antibody confirmed that only single full-length sfGFP 
(27 kD) species was present in the extracts (Fig. 2C). A possible explanation for this 
fluorescence decay is non-specific unfolding or aggregation of sfGFP within the cell-
extract. 
 
3.3 TX-TL synthesis of the OxyB, -C, -D, -J, ȂK and ȂT enzymes 
To test the ability of S. venezuelae TX-TL to synthesise proteins from secondary 
metabolism, a selection of genes (oxyB, -C, -D, -J, -K and ȂT) from the S. rimosus 
oxytetracycline pathway [20] were assembled by Golden Gate with a T7 promoter, strong 
RBS and C-terminal His6-tag. In addition, a T7-driven sfGFP (-/+ His6-tag) was used as a 
positive control, with T7 RNA polymerase added to the S. venezuelae extracts to drive 
mRNA synthesis. Interestingly, for all of the oxytetracycline enzymes OxyB ȂC, D, -J, -K, -T 
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and sfGFP, these were detected by Western blotting as full-length His6-tagged proteins 
(Fig. 2D), ranging in size from 12 kDa (OxyC) to 70 kDa (OxyD). This provided an 
indication of the potential of S. venezuelae TX-TL to synthesise high G+C (%) genes from 
secondary metabolism. In comparison, with E. coli TX-TL, although higher yields (~2-10 
PM) of sfGFP and the OxyB, -C, -J, -K and ȂT proteins were obtained, the OxyD protein 
could not be detected. For further information please refer to Supporting information Fig. 
S3.  
 
3.4 Inducible gene expression with the TetR system 
Utilising the Tn10-derived TetR gene expression tool [19], we introduced a tetO operator 
site immediately downstream of the kasOp* promoter. By assembling this synthetic 
promoter with sfGFP, an anhydrotetracycline (aTC) inducible gene expression tool was 
rapidly prototyped in S. venezuelae TX-TL by utilising purified cognate TetR repressor, aTC 
and the TX-TL reaction components (Fig. 3). Firstly, 20 nM kasOp*-tetO synthetic 
promoter produces 3.5-fold less sfGFP in comparison to the equivalent kasOp*-sfGFP 
control plasmid (20 nM) lacking the tetO operator. Additionally, gene expression from the 
kasOp*-sfGFP plasmid is unaltered with either TetR (5 PM) or 1 PM aTC, whilst a 26% 
decrease in signal is observed with 10 PM aTC. However, in the presence of the tetO 
operator coupled to the kasOp* promoter and sfGFP, a clear switch-off in gene expression 
is observed by titrating an increasing concentration of TetR (1-5 PM), which was 
recovered by the presence of aTC (1-10 PM). 
 
3.5 Concluding remarks 
Herein, we have developed a S. venezuelae TX-TL system as a new tool for synthetic 
biology. This system demonstrates high-yield synthesis of sfGFP (up to 1.3 PM) and a 
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range of enzymes from the oxytetracycline pathway, using a simple and cost-efficient 
protocol for extract preparation. The development of a S. venezuelae TX-TL system 
potentially provides a fast route to obtaining enzymes from Streptomyces secondary 
metabolism using a homologous host for protein folding. Whilst each protein target is 
unique, we will investigate this tool for the synthesis of specialised enzymes that require 
post-translational modification [10,11] or exotic precursors for protein folding, such as 
coenzyme F420 [12]. We will now focus on enhancing this initial S. venezuelae TX-TL 
platform, prototype gene circuits and investigate its use for the characterisation of cryptic 
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Figure 1. A protocol for S. venezuelae TX-TL. (A) Schematic overview of cell-extract 
preparation. Optimisation of (B) Mg-/K-glutamate, (C) PEG, (D) run-off reaction, (E) 
sonication and (F) dialysis conditions, with 10 nM of kasOp*-sfGFP plasmid. Errors bars 
(standard deviation) are representative of three biological and three technical repeats. (G) 
Batch variation between cell-extracts with 40 nM of kasOp*-sfGFP plasmid.  
 
Figure 2. Saturation of S. venezuelae TX-TL occurs at 20-40 nM DNA. (A) Time-course 
reaction with increasing DNA concentration. (B) Saturation curve of end-point samples 
with Extracts A-C. Errors bars (standard deviation) are representative of three technical 
repeats. (C) Western blot of end-point TX-TL samples with mouse anti-GFP primary 
antibody. Lane abbreviations: M, PageRuler Plus (ThermoFisher) and purified His6-sfGFP 
was used as a positive control (29 kDa). (D) Western blot of S. venezuelae and E. coli TX-TL 
of sfGFP and oxytetracycline enzymes. Red star (*) indicates negative synthesis of OxyD in 
E. coli TX-TL. Positive bands are individually cropped, with the original blots and SDS-
PAGE gels shown in Supporting Information Fig. S3. 
 
Figure 3. Synthetic TetO/TetR gene expression in S. venezuelae TX-TL. (A) Plasmid design 
of the kasOp*-tetO synthetic promoter. (B) Purified TetR and aTC was spiked into S. 
venezuelae TX-TL to modulate gene expression. (C) End-point readings of sfGFP with 
varied TetR and aTC concentrations in combination with the kasOp*-tetO-sfGFP plasmid. 
aTC inhibition with (D) kasOp*-sfGFP and (E) kasOp*-tetO-sfGFP. (F) Repression with TetR 
and (G) release with 1 PM aTC (non-inhibitory level). Errors bars (standard deviation) are 
representative of three technical repeats. 
 
